Hyperphosphatemia - Epidemiology Forecast - 2036

Hyperphosphatemia Insights and Trends

• Hyperphosphatemia is highly prevalent among patients with advanced CKD and ESRD, with risk increasing progressively as renal function declines due to impaired phosphate excretion.
• According to the NIDDK, CKD prevalence in the US increased from approximately 12% to 14% between 1988-1994 and 1999-2004 and has remained relatively stable thereafter; notably, nearly 90% of CKD patients remain unaware of their condition, contributing to delayed diagnosis and phosphate imbalance progression.
• The prevalence of ESRD has increased substantially over recent decades, with nearly 71% of ESRD patients receiving dialysis therapy, representing a major at-risk population for hyperphosphatemia and associated cardiovascular complications.

DelveInsight's 'Hyperphosphatemia - Epidemiology Forecast - 2036' report delivers an in-depth understanding of the Hyperphosphatemia, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Hyperphosphatemia Understanding and Diagnosis Algorithm

Hyperphosphatemia Overview and Diagnosis

Hyperphosphatemia is a metabolic disorder characterized by elevated serum phosphate levels, most commonly occurring in patients with advanced chronic kidney disease (CKD) and end-stage renal disease (ESRD) due to impaired renal phosphate excretion. The condition is strongly associated with CKD-mineral and bone disorder (CKD-MBD), secondary hyperparathyroidism, vascular calcification, and increased cardiovascular risk. Persistent hyperphosphatemia contributes significantly to morbidity and mortality in dialysis patients. Current management includes dietary phosphate restriction, dialysis optimization, and phosphate binders; however, long-term phosphate control remains challenging because of high pill burden and tolerability issues. The growing CKD and dialysis population continues to increase the clinical and economic burden of hyperphosphatemia.

Hyperphosphatemia Diagnosis

Hyperphosphatemia is diagnosed primarily through serum phosphate testing, with elevated phosphate levels indicating impaired phosphate regulation, most commonly in patients with advanced CKD and ESRD. Diagnosis is supported by evaluation of kidney function, serum calcium, parathyroid hormone (PTH), and vitamin D levels to assess associated CKD-mineral and bone disorder (CKD-MBD). Routine phosphate monitoring is recommended in dialysis and advanced CKD patients due to the strong association of persistent hyperphosphatemia with vascular calcification, cardiovascular complications, and increased mortality risk.

Hyperphosphatemia Epidemiology

Key Findings from Hyperphosphatemia Epidemiological Analysis and Forecast

• According to DelveInsight, in 2025, in the United States, the prevalent cases of CKD were found to be highest in the age group 65 and above with approximately 1,961,000 cases and followed by age group 45-64 with approximately 1,056,000 cases.
• There are five stages of CKD defined as Stage 1-5. As per the CDC estimates, the prevalence of ESRD doubled between 1990 and 2016. Secondary findings in 2016 suggested a point prevalence of 2,206 per million population for the ESRD treated pool; the prevalence of dialysis treatment was 1,553 per million, whereas the prevalence of functioning kidney transplant was 653 per million. Furthermore, nearly 71% of patients are on dialysis, and 29% live with a kidney transplant.
• In a large community-based cohort study from the QICKD trial, hyperphosphatemia (>1.50 mmol/L) was observed in 4.3% of patients with CKD stages I-II and 22.4% of patients with CKD stages III-V who experienced cardiovascular events, highlighting the increasing burden of hyperphosphatemia with worsening CKD severity.
• Hyperphosphatemia is observed in approximately 1.4% of patients with CKD stages I-II, while its prevalence increases to around 2.3% in patients with CKD stages III-IV.
• Elevated serum phosphate levels are associated with increased risks of vascular calcification, cardiovascular disease, all-cause mortality, and hospitalization, particularly among dialysis-dependent CKD populations.
• Hyperphosphatemia is a common laboratory abnormality encountered by nephrologists. In patients with ESRD, the prevalence of hyperphosphatemia varies from 50 to 74%. Among children with oncologic disorders who received liposomal amphotericin, nearly 45% of children developed hyperphosphatemia.

Scope of the Report:

• The report covers a segment of a descriptive overview of hyperphosphatemia, explaining their causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Hyperphosphatemia Patient Population Forecast

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• 11-year Forecast
• Patient Burden Trends (by geography)

FAQs:

• What are the disease risks, burdens, and unmet needs of hyperphosphatemia? What will be the growth opportunities across the 7MM concerning the patient population with hyperphosphatemia?
• What is the historical and forecasted Hyperphosphatemia patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy:

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders' perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.